<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145234</url>
  </required_header>
  <id_info>
    <org_study_id>CN001-001</org_study_id>
    <nct_id>NCT02145234</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immunogenicity,
      pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy
      adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose - other: Protocol designed to assess the safety, tolerability,
      immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-986089 in healthy
      subjects

      Enrollment: Single ascending dose panels: 48 subjects, Multiple ascending dose panels: 96

      Minimum age: 18 years (Elderly MAD Panel 65 years of age) Maximum age: 55 years (Elderly MAD
      Panel 70 years of age)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2014</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations</measure>
    <time_frame>Single Ascending Dose (SAD) Phase 119 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations</measure>
    <time_frame>Multiple Ascending Dose (MAD) phase 148 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration 168 h post dose (C(168H)) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of terminal phase (if IV and if multi-exponential decline) (Vz/F) for SAD</measure>
    <time_frame>SAD phase: Day1 to Day 91</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T-Half) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration 336 h post dose (C(336H)) for SAD and MAD</measure>
    <time_frame>SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation or Fluctuation Index (DF) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css-Avg) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI AUC) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax Accumulation Index; ratio of Cmax at steady-state to Cmax after the first dose (AI Cmax) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(168H) Accumulation Index; ratio of C168H at steady-state to C168H after the first dose (AI C168H) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C(336H) Accumulation Index; ratio of C(336H) at steady-state to C(336H) after the first dose (AI 336H) for MAD</measure>
    <time_frame>MAD phase: Day 1 to Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of single and multiple doses of BMS-986089 will be measured by testing for the presence of ADAs for SAD and MAD</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic effect of single and multiple doses of BMS-986089 on free myostatin, total myostatin (pre-dose only), and myostatin-drug complex will be assessed by measuring these biomarkers for SAD and MAD</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in a single subcutaneous administration
OR
Placebo matching with BMS-986089 in a single subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administration every 2 weeks
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 in multiple subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986089 a single subcutaneous administrations weekly
OR
Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986089</intervention_name>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-986089</intervention_name>
    <arm_group_label>SAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>SAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 1:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 2:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 3:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 4:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 5:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 6:BMS-986089/Placebo</arm_group_label>
    <arm_group_label>MAD Panel 7:BMS-986089/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal
             medical history, physical examination, ECGs and clinical laboratory determinations

          -  Men and women who are not of childbearing potential (ie, who are postmenopausal or
             Surgically sterile WOCBP) ages 21 to 55 years

          -  Women must not be breastfeeding

          -  Men who are sexually active with women of child bearing potential (WOCBP) must use any
             contraceptive method with a failure rate of less than 1% per year

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness Any major surgery within 6 weeks of
             study drug administration

          -  Any condition that will clearly require medical or surgical treatment during the
             period of study participation

          -  Any bone trauma or bone surgery within 3 months of study drug administration

          -  Known or suspected autoimmune disorder

          -  Donation of blood or plasma to a blood bank or in a clinical study (except at
             screening visit) within 6 weeks of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wcct Global, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

